Terms: = Bone cancer AND MAF, MGC71685, 4094, ENSG00000178573 AND Treatment
14 results:
1. Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology.
Coleman R
J Bone Miner Metab; 2023 May; 41(3):290-300. PubMed ID: 37162605
[TBL] [Abstract] [Full Text] [Related]
2. Targeting the oncogenic transcription factor c-maf for the treatment of multiple myeloma.
Jiang Q; Mao H; He G; Mao X
Cancer Lett; 2022 Sep; 543():215791. PubMed ID: 35700821
[TBL] [Abstract] [Full Text] [Related]
3. Local anesthetic levobupivacaine inhibits stemness of osteosarcoma cells by epigenetically repressing mafB though reducing KAT5 expression.
Wang Z; Song Y; Zhang H; Yang Y; Zhang S; Wang W
Aging (Albany NY); 2022 Mar; 14(6):2793-2804. PubMed ID: 35333774
[TBL] [Abstract] [Full Text] [Related]
4.
Paterson AHG; Lucas PC; Anderson SJ; Mamounas EP; Brufsky A; Baez-Diaz L; King KM; Lad T; Robidoux A; Finnigan M; Sampayo M; Tercero JC; Mairet JJ; Wolff AC; Fehrenbacher L; Wolmark N; Gomis RR
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34377934
[TBL] [Abstract] [Full Text] [Related]
5. Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma.
Jia Y; Zhou J; Tan TK; Chung TH; Wong RWJ; Chooi JY; Lim JSL; Sanda T; Ooi M; De Mel S; Soekojo C; Chen Y; Zhang E; Cai Z; Shen P; Ruan J; Chng WJ
Blood Cancer J; 2021 Feb; 11(2):32. PubMed ID: 33579893
[TBL] [Abstract] [Full Text] [Related]
6. High maf of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract] [Full Text] [Related]
7. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract] [Full Text] [Related]
8. mafb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Qiang YW; Ye S; Huang Y; Chen Y; Van Rhee F; Epstein J; Walker BA; Morgan GJ; Davies FE
BMC Cancer; 2018 Jul; 18(1):724. PubMed ID: 29980194
[TBL] [Abstract] [Full Text] [Related]
9. Effect of maf amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
Coleman R; Hall A; Albanell J; Hanby A; Bell R; Cameron D; Dodwell D; Marshall H; Jean-Mairet J; Tercero JC; Rojo F; Gregory W; Gomis RR
Lancet Oncol; 2017 Nov; 18(11):1543-1552. PubMed ID: 29037984
[TBL] [Abstract] [Full Text] [Related]
10. Harnessing the Therapeutic Potential of Th17 Cells.
Bystrom J; Taher TE; Muhyaddin MS; Clanchy FI; Mangat P; Jawad AS; Williams RO; Mageed RA
Mediators Inflamm; 2015; 2015():205156. PubMed ID: 26101460
[TBL] [Abstract] [Full Text] [Related]
11. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.
Lu G; Muddasani R; Orlowski RZ; Abruzzo LV; Qazilbash MH; You MJ; Wang Y; Zhao M; Chen S; Glitza IC; Medeiros LJ
Arch Pathol Lab Med; 2013 May; 137(5):625-31. PubMed ID: 23627452
[TBL] [Abstract] [Full Text] [Related]
12. Targeted therapy of multiple myeloma.
Dolloff NG; Talamo G
Adv Exp Med Biol; 2013; 779():197-221. PubMed ID: 23288641
[TBL] [Abstract] [Full Text] [Related]
13. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
Nakashima T; Ishii T; Tagaya H; Seike T; Nakagawa H; Kanda Y; Akinaga S; Soga S; Shiotsu Y
Clin Cancer Res; 2010 May; 16(10):2792-802. PubMed ID: 20406843
[TBL] [Abstract] [Full Text] [Related]
14. Triple drug chemotherapy for advanced ovarian carcinoma: comparative study of two regimens.
Aroney RS; Levi JA; Dalley DN
Med J Aust; 1981 Jun; 1(12):633-5. PubMed ID: 7019638
[TBL] [Abstract] [Full Text] [Related]
